CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Submucosal Bevacizumabdrug
Likely dose
Submucosal Bevacizumab 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01402531
NCT01402531Phase 2Completed
CompareCT.gov

Submucosal Bevacizumab for the Management of Recurrent Epistaxis in Patients With Hereditary Hemorrhagic Telangiectasia (HHT)

University of California, San Diego·interventional·Posted Jul 26, 2011·Updated Dec 4, 2019

In Brief

A Phase 2 clinical trial evaluating Submucosal Bevacizumab for Hereditary Hemorrhagic Telangiectasia (HHT). Completed, enrolled 10 participants across 1 site.

Detailed Summary

This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with Hereditary Hemorrhagic Telangiectasia (HHT).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Hemorrhagic Telangiectasia (HHT)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJul 26, 2011
Enrollment StartJul 22, 2010
Primary CompletionJul 27, 2013
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 14.9 years ago

Interventions

Submucosal Bevacizumabdrug

200 mg Bevacizumab, injected submucosally- 100 mg per nostril